Evogene Ltd (EVGN)
Evogene Ltd. is a biotechnology company listed on NASDAQ under the ticker EVGN. Based in Rehovot, Israel, it operates through three business segments: Agriculture, Human Health, and Industrial Applications. The company applies computational biology and AI-based tools, including its ChemPass AI generative engine, to support the design of novel small molecules for drug development. Its agricultural activities include seed traits and crop-protection chemicals, while its industrial work includes the development and commercialization of castor bean seeds for industrial uses. Evogene also develops medical cannabis products and has a collaboration with LMU University Hospital Munich focused on potential therapies for hyper-inflammatory diseases linked to dysregulated neutrophil activity, including inflammatory bowel disease. Founded in 1999, the company operates across Israel, the United States, Europe, and Africa.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EVGN
|
$0.57
|
16.2% Upside
|
Fair
|
$2.15
|
335.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
4.6x
|
7.618 M
|
9.443 M
|
10.7%
|
91.5%
|
-69.7
|
61.5%
|
